GSK to Feature Results from the P-III (ZOSTER-049) Study of Shingrix for Protection Against Shingles at ESCMID Global 2024
Shots:
- GSK will present data from the P-III (ZOSTER-049) study following individuals for ~11yrs. post initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV) at ESCMID Global 2024
- The P-III (ZOSTER-049) study assessed the safety, efficacy & immunogenicity of Shingrix in individuals (n=7000, ≥50yrs.) for an additional 6yrs. following the conclusion of ZOE-50 & ZOE-70 trials, making it a total of ~11yrs. of follow-up
- The study demonstrated a vaccination efficacy (VE) of 79.7% from 6 to 11yrs. and 82.0% at 11yrs. in adults ≥50yrs. of age. Vaccination efficacy was 73.1% in adults ≥70yrs. of age from 6 to 11yrs. showing greater VE rates among all groups
Ref: GSK | Image: GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
